MedDataX Logo

Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders

NCT ID: NCT00677573

Last Updated: 2008-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We proposed to compare outcomes in women with DOR undergoing ART with rec-FSH + u-HMH with those with u-FSH only in GnRH antagonist protocols.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ART poor responder GnRH antagonist Gonadotropins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UrFSH

Group Type ACTIVE_COMPARATOR

Fostimon

Intervention Type DRUG

450 IU for 4 days then adjusted

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fostimon

450 IU for 4 days then adjusted

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least one trial with adequate ovarian stimulation resulted by 4 or less oocytes retrieval.

Exclusion Criteria

* High responder patients
Minimum Eligible Age

20 Years

Maximum Eligible Age

44 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bahceci Women Health Care Center

UNKNOWN

Sponsor Role collaborator

German Hospital, Istanbul

OTHER

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alman Hastanesi

Istanbul, Istanbul, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ulun Ulug, M.D.

Role: CONTACT

Phone: 90-21-2293-2150

Email: [email protected]

Mustafa Bahceci, M.D

Role: CONTACT

Phone: 90-21-2230-0809

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Haluk Toygarlı, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ughno1

Identifier Type: -

Identifier Source: org_study_id